These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 27514314)

  • 1. Rationale and protocol of AIRC IG-13218, short-term radiotherapy for early prostate cancer with concomitant boost to the dominant lesion.
    Timon G; Ciardo D; Bazani A; Garioni M; Maestri D; De Lorenzo D; Pansini F; Cambria R; Rondi E; Cattani F; Marvaso G; Zerini D; Vischioni B; Ciocca M; Russo S; Molinelli S; Golino F; Scroffi V; Rojas DP; Fodor C; Petralia G; Santoro L; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Tumori; 2016 Oct; 102(5):536-540. PubMed ID: 27514314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218.
    Timon G; Ciardo D; Bazani A; Marvaso G; Riva G; Volpe S; Rojas DP; Renne G; Petralia G; Zerini D; Fodor C; Dicuonzo S; Maestri D; Pansini F; Cambria R; Cattani F; Golino F; Scroffi V; De Lorenzo D; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Br J Radiol; 2018 Sep; 91(1089):20160725. PubMed ID: 29750539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II prospective trial "Give Me Five" short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218).
    Marvaso G; Gugliandolo SG; Bellerba F; Gandini S; Corrao G; Volpe S; Rojas DP; Riva G; Zerini D; Pepa M; Fodor CI; La Rocca E; Pricolo P; Alessi S; Petralia G; Mistretta FA; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
    Med Oncol; 2020 Jul; 37(8):74. PubMed ID: 32725443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients.
    Marvaso G; Jereczek-Fossa BA; Vischioni B; Ciardo D; Giandini T; Hasegawa A; Cattani F; Carrara M; Ciocca M; Bedini N; Villa S; Morlino S; Russo S; Zerini D; Colangione SP; Panaino CMV; Fodor C; Santoro L; Pignoli E; Valvo F; Valdagni R; De Cobelli O; Orecchia R
    Tumori; 2017 May; 103(3):314-318. PubMed ID: 28009421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying the dominant prostate cancer focal lesion using image analysis and planning of a simultaneous integrated stereotactic boost.
    Feng Y; Welsh D; McDonald K; Carruthers L; Cheng K; Montgomery D; Lawrence J; Argyle DJ; McLaughlin S; McLaren DB; Nailon WH
    Acta Oncol; 2015; 54(9):1543-50. PubMed ID: 26397055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
    Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
    Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Tumor Control and Late Toxicity in Patients with Prostate Cancer Receiving Hypofractionated (2.2 Gy) Soft-tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Shimizu D; Yamazaki H; Nishimura T; Aibe N; Okabe H
    Anticancer Res; 2017 Oct; 37(10):5829-5835. PubMed ID: 28982908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis.
    Corrao G; Marvaso G; Zaffaroni M; Volpe S; Augugliaro M; Fodor CI; Zerini D; Vingiani A; Mistretta FA; Luzzago S; Alessi S; Pricolo P; Musi G; De Cobelli O; Renne G; Manzoni M; Petralia G; Orecchia R; Jereczek-Fossa BA
    Neoplasma; 2022 Mar; 69(2):404-411. PubMed ID: 35014537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose constraints for moderate hypofractionated radiotherapy for prostate cancer: The French genito-urinary group (GETUG) recommendations.
    Langrand-Escure J; de Crevoisier R; Llagostera C; Créhange G; Delaroche G; Lafond C; Bonin C; Bideault F; Sargos P; Belhomme S; Pasquier D; Latorzeff I; Supiot S; Hennequin C
    Cancer Radiother; 2018 Apr; 22(2):193-198. PubMed ID: 29628205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated boost to the dominant tumor region with intensity modulated stereotactic radiotherapy for prostate cancer: a sequential dose escalation pilot study.
    Miralbell R; Mollà M; Rouzaud M; Hidalgo A; Toscas JI; Lozano J; Sanz S; Ares C; Jorcano S; Linero D; Escudé L
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):50-7. PubMed ID: 19910135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
    Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated radiotherapy for organ-confined prostate cancer: is less more?
    Arcangeli S; Greco C
    Nat Rev Urol; 2016 Jul; 13(7):400-8. PubMed ID: 27296648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V; Villeirs G; Speleers B; De Neve W; De Wagter C; Lumen N; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):799-807. PubMed ID: 18407430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol.
    Mott JH; Livsey JE; Logue JP
    Br J Radiol; 2004 May; 77(917):377-86. PubMed ID: 15121701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderate hypofractionation and simultaneous integrated boost by helical tomotherapy in prostate cancer: monoinstitutional report of acute tolerability assessment with different toxicity scales.
    Ferrera G; Mortellaro G; Mannino M; Caminiti G; Spera A; Figlia V; Iacoviello G; Di Paola G; Mazzola R; Lo Casto A; Alongi F; Pappalardo MP; Lagalla R
    Radiol Med; 2015 Dec; 120(12):1170-6. PubMed ID: 26002724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity.
    Rudat V; Nour A; Hammoud M; Alaradi A; Mohammed A
    Strahlenther Onkol; 2016 Feb; 192(2):109-17. PubMed ID: 26545764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.
    Pathmanathan AU; Alexander EJ; Huddart RA; Tree AC
    Future Oncol; 2016 Nov; 12(21):2495-2511. PubMed ID: 27322113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.